Showing 261-270 of 18069 results for "".
The Diabetic Investor
https://reachmd.com/programs/clinicians-roundtable/the-diabetic-investor/1642/Join host Larry Kaskel interview David Kliff, a diabetic himself and the publisher of the Diabetic Investor. Should you invest in the Diabetes Sector? What drug companies will pick up the Avandia business? Find out in this segment.New Treatments for Peripheral Diabetic Neuropathy
https://reachmd.com/programs/diabetes-discourse/new-treatments-for-peripheral-diabetic-neuropathy/4691/Diabetic peripheral neuropathy remains one of the most common complications in diabetes. Because type 2 diabetes often goes undiagnosed for many years, it is common for patients to present with some degree of neuropathy. Our guest, podiatrist, specializing in diabetic foot problems, Dr. Ingrid KruseInpatient and Outpatient Recommendations for Diabetes
https://reachmd.com/programs/diabetes-discourse/inpatient-and-outpatient-recommendations-for-diabetes/6461/The transition from hospital to home for patients with diabetes can be challenging, from glycemic targets, guidelines for initiating insulin therapy, the various types of insulin and oral agents to general nutrition. What are the current recommendations for the transition from hospital to home for pThe Benefits of Moderate Weight Loss in Diabetes
https://reachmd.com/programs/diabetes-discourse/the-benefits-of-moderate-weight-loss-in-diabetes/5344/Patients with type 2 diabetes struggle to lose or maintain weight, especially with particular therapies. What are some of the successful therapeutic interventions available for overweight patients with type 2 diabetes? What are the potential health effects of the loss of even 5 to 10 pounds for thesThe Challenges of Diagnosing Diabetes in Children
https://reachmd.com/programs/diabetes-discourse/the-challenges-of-diagnosing-diabetes-in-children/4688/The incidence of diabetes is increasing per year in the US and globally. The trend data suggests that obesity may be driving autoimmune beta cell failure. Some have questioned whether excess obesity or adiposity might be playing a role in this increased incidence of type 1 diabetes or whether healthLong Term Efficacy and Safety of Laronidase for MPS I
https://reachmd.com/programs/clinicians-roundtable/long-term-efficacy-and-safety-of-laronidase-for-mps-i/4755/Host Dr. Bruce Bloom welcomes Dr. Emil Kakkis, an advisor at BioMarin Pharmaceutical Inc. and author of numerous published articles on mucopolysaccharidosis I, or MPS I, to discuss current treatment options. They discuss the benefits and risks of enzyme replacement therapy with laronidase. Don't misMusculoskeletal Aspects of MPS I: Diagnosis and Management Considerations
https://reachmd.com/programs/clinicians-roundtable/musculoskeletal-aspects-of-mps-i-diagnosis-and-management-considerations/4758/What are the musculoskeletal signs and symptoms in children with MPS I? How can we test for MPS I? And how does the disease present in patients as they grow up? Dr. Gregory M. Pastores, associate professor of neurology and pediatrics at the New York University School of Medicine in New York, and dirPedophilia -Types and Classifications
https://reachmd.com/programs/clinicians-roundtable/pedophilia-types-and-classifications/408/Dr. Ryan Hall, a senior resident from the Department of Psychiatry and Behavioral Sciences at John Hopkins University defines pedophilia and classifies distinctions between the different types.Biomolecular Advances in Diabetes Prevention
https://reachmd.com/programs/focus-on-diabetes/biomolecular-advances-in-diabetes-prevention/6098/As the epidemic of type 2 diabetes in the United States grows, researchers are investigating hundreds of ways to treat and cure diabetes. Some of these methods include exogenous insulin, while other ideas being explored require more complex changes in our understanding of cellular biology. Dr. CarmeDecoding Diabetes Diversity: A Study on Heterogeneity and Endotypes in T1D
https://reachmd.com/programs/diabetes-discourse/decoding-diabetes-diversity-a-study-on-heterogeneity-and-endotypes-in-t1d/16254/Tune in for an in-depth review of a recent paper focusing on the heterogeneity and endotypes in type 1 diabetes.